Institutional shares held 171 Million
625K calls
739K puts
Total value of holdings $1.47B
$5.38M calls
$6.36M puts
Market Cap $1.62B
185,944,992 Shares Out.
Institutional ownership 91.93%
# of Institutions 284


Latest Institutional Activity in BCRX

Top Purchases

Q4 2024
Charles Schwab Investment Management Inc Shares Held: 1.98M ($17.3M)
Q4 2024
Ieq Capital, LLC Shares Held: 29.4K ($257K)
Q4 2024
Proficio Capital Partners LLC Shares Held: 25.6K ($223K)
Q4 2024
Quest Partners LLC Shares Held: 28.4K ($248K)
Q4 2024
Principal Financial Group Inc Shares Held: 17.8K ($155K)

Top Sells

Q4 2024
Gw&K Investment Management, LLC Shares Held: 2.94M ($25.7M)
Q4 2024
Fisher Asset Management, LLC Shares Held: 3.18M ($27.8M)
Q4 2024
Gsa Capital Partners LLP Shares Held: 164K ($1.44M)
Q4 2024
Sg Americas Securities, LLC Shares Held: 41.4K ($361K)
Q4 2024
Inspire Investing, LLC Shares Held: 53.5K ($467K)

About BCRX

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.


Insider Transactions at BCRX

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
1.13M Shares
From 25 Insiders
Grant, award, or other acquisition 922K shares
Open market or private purchase 184K shares
Bona fide gift 20K shares
Sell / Disposition
141K Shares
From 10 Insiders
Open market or private sale 27K shares
Payment of exercise price or tax liability 94.4K shares
Bona fide gift 20K shares

Track Institutional and Insider Activities on BCRX

Follow BIOCRYST PHARMACEUTICALS INC and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells BCRX shares.

Notify only if

Insider Trading

Get notified when an Biocryst Pharmaceuticals Inc insider buys or sells BCRX shares.

Notify only if

News

Receive news related to BIOCRYST PHARMACEUTICALS INC

Track Activities on BCRX